2019
An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer
Zhang J, Qu Z, Yao H, Sun L, Harata-Lee Y, Cui J, Aung TN, Liu X, You R, Wang W, Hai L, Adelson DL, Lin L. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer. Biomedicine & Pharmacotherapy 2019, 118: 109169. PMID: 31310954, DOI: 10.1016/j.biopha.2019.109169.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsAutophagyCarcinoma, Non-Small-Cell LungCell Line, TumorCell SurvivalDown-RegulationDrug Resistance, NeoplasmDrugs, Chinese HerbalGefitinibGene Expression Regulation, NeoplasticHumansLung NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesUp-RegulationConceptsNon-small cell lung cancerCompound Kushen InjectionPI3K/AKT/mTOR pathwayCell lung cancerAKT/mTOR pathwayLung cancerGefitinib treatmentMTOR pathwayFirst-line treatment optionDrug sensitivityPositive EGFR mutationDose-dependent fashionSensitive cell linesMost patientsTreatment optionsEGFR mutationsKushen InjectionTreatment relapseSensitizing agentGefitinibCancerRegulation of autophagyDown regulationTreatment effectsPatients
2017
Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action
Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. International Journal Of Molecular Sciences 2017, 18: 656. PMID: 28304343, PMCID: PMC5372668, DOI: 10.3390/ijms18030656.Peer-Reviewed Original ResearchConceptsAnti-cancer agentsNatural compound mixturesTherapeutic benefitCancer progressionCancer cellsSynergistic therapeutic benefitsPotential molecular targetsPositive therapeutic benefitsAberrant apoptotic pathwaysClinical efficacyTreatment of cancerAdverse reactionsCancer managementMerit further investigationMultiple specific targetsDrug resistanceCancerGenetic abnormalitiesEffective dosageLimited evidenceMolecular targetsScientific evidenceApoptotic mechanismsFurther investigationProgression